Precigen/$PGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Ticker

$PGEN
Primary listing

Industry

Biotechnology

Employees

143

ISIN

US74017N1054

Precigen Metrics

BasicAdvanced
$440M
-
-$0.56
1.82
-

What the Analysts think about Precigen

Analyst ratings (Buy, Hold, Sell) for Precigen stock.

Bulls say / Bears say

FDA granted Priority Review to Precigen's Biologics License Application (BLA) for PRGN-2012, with a PDUFA target action date set for August 27, 2025, indicating potential for expedited approval and market entry. (Precigen Press Release)
Precigen completed a $30.9 million public offering in August 2024, bolstering its financial position to support the commercialization of PRGN-2012. (Nasdaq)
Institutional investors, such as LexAurum Advisors LLC, have increased their holdings in Precigen, reflecting confidence in the company's future prospects. (MarketBeat)
Precigen reported a net loss of $126.2 million for the year ended December 31, 2024, compared to a net loss of $95.9 million in the previous year, indicating widening losses. (Precigen Press Release)
The company recorded a $5.8 million impairment charge related to its Exemplar subsidiary in Q4 2024, suggesting challenges in certain business segments. (Precigen Press Release)
Precigen underwent a strategic prioritization, including a reduction of over 20% of its workforce, which may indicate operational challenges and potential disruptions. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

Precigen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Precigen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PGEN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs